HOME > TOP STORIES

TOP STORIES

REGULATORY DPP Vows to Scrap Off-Year Drug Price Revisions in Election Platform

January 23, 2026
REGULATORY Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability

January 22, 2026
REGULATORY PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations

January 21, 2026
ORGANIZATION OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs

January 20, 2026
REGULATORY AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery

January 20, 2026
REGULATORY Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote

January 20, 2026
REGULATORY Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts

January 19, 2026
REGULATORY Expert Calls for Full Verification of CEA Guidelines and Analytical Frameworks

January 16, 2026
REGULATORY Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys

January 15, 2026
BUSINESS Rohto to Roll Out 3- or 4-Day Workweek Option from April to Spur Growth, Retention

January 15, 2026
ORGANIZATION Pharma FTC Clarifies “Simple Beverages” under New Food Rules

January 14, 2026
REGULATORY Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23

January 13, 2026
REGULATORY MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred

January 9, 2026
BUSINESS Bayer/Santen to Launch Eylea Bio-AG on February 2

January 9, 2026
BUSINESS Pharma Leaders Press for Drug Pricing Overhaul at New Year’s Confab

January 8, 2026
BUSINESS Generic Entry into DPP-4 Class Poised to Accelerate in 2026

January 7, 2026
COMMENTARY Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

January 6, 2026
ORGANIZATION FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair

January 6, 2026
ORGANIZATION Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair

January 6, 2026
ORGANIZATION Industry Leaders Call for Proper Rewards for Innovation in New Year Messages

January 5, 2026

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key

By Sakura Kono

Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…